Investment Q&A

Q: ESSA Pharma is just one example of an exciting pharma in a topically interesting (prostate cancer, aging population…) area but with impenetrable valuation characteristics. Can you say whether this stock’s prospects are worth its price? Are there other early-stage pharmas you like?

Q: would like your view on rx, last i could find was may 2023.
thank you

Q: IDEAYA Biosciences, Inc. (IDYA). Please give me your opinion about this company for next three to five years. Thanks

Q: Would you be able to please comment on LMAT (NASDAQ)? I believe the balance sheet is good, and about 10% insider ownership.

Is valuation okay vs it's growth rate? Do you see any concerning competition in their business? Any other comments?

Q: I am looking for new healthcare stocks after selling Lantheus and InMode in the last 6 months. I currently own WELL. Quite a few have had a good run up lately so not sure if they are good buys at current valuations. What are recommendations? US or CAD, doesn’t matter. Should I buy an ETF instead?
Thank you in advance

Q: Hi 5i
Currently a share holder of WBA....
Regarding previous 5i comments about WBA, its debt and large dividend.......
Now that WBA has cut dividend by nearly 50%, where do you see it going from here?
Is it a good time to consider or still require wait and see? Attractive entry point at what price?
What has to happen next in this story?
Thx
jim

Q: With Rexall up for sale, who do you feel could be potential buyers. Do you see NBLY in the bidding with the takeover in play?

Q: Morning 5iTeam,

Would you please comment on UHN's earnings and how how the stock will perform going forward.
Thanks,
H

Q: What are your thoughts on the Biotech ETC here? I have heard the argument that biotech is very beaten down, and that lowering of interest rates tends to booster the sector quite a bit, especially once IPOs begin to happen again.

Q: Can I get you option on Lantheus after they released preliminary fiscal year 2023. Buy, hold, or sell? Thank you

Q: This company seems to be doing a lot of things right. The ceo Dan Matlow knows this space well, based on my conversations with him a few years ago. It's business is primarily in the UK but it is making some inroads in Ontario. How does one go about evaluating this business: what comparable companies and what ratios etc do you use? Thank you as I am not very good at determining values in the software industry.

Q: Hi,

I'm low on healthcare according to the analytics tool. I have held XHC for a few years now and it's showing just a small gain. Is there anything a bit more "growthy" or should I just add to XHC?

Thanks
Robert

Q: I would like your opinion on Apellis Pharmaceuticals. I read Citron's research piece (was published in November) on this company new product -Syfovre- issues and make a little bit of research myself. Obviously Citron is mostly promotting its own short positions but this one seems a reasonnable bet considering the content of the report (see attached link). No warning letter yet by the FDA but it is surely a real possibility.


Thank you!

Michel C

https://citronresearch.com/wp-content/uploads/2023/11/Citron-Reports-on-Apellis-Pharmaceuticals.pdf

Q: Can you provide your comments and outlook for this name

Q: after the recent reverse split and additional financing, how many total shares are now outstanding and what % owned by insiders if available. Thanks

Q: I have owned Theratechnologies since 2018 and watched this stock fall since I purchased it. The stock has been rising the last few weeks and was up 23% on Friday. I couldn't find any exciting press releases that would explain the increase. Do you know of any reason for the recent increase?

The 5 analysts listed on Qtrade have a price target of anywhere from $5.50-$12.04. How much faith can we put in the price targets of analysts?

I was quite excited that it was up to $3.03 but just noticed there was a 4 for 1 stock split in August 2023 so my 700 shares are now only 175 shares. So rather than being down 60% I am actually down 90%. Yikes, I better not tell my wife about this trade!

My holdings in TH are only worth $530 now. Should I sell this loser now or is it worth waiting until the annual report (November year end) comes out?

Q: seems like a bit of a long shot high volume some analysts have high expectations could you comment please?

Q: Your thoughts on why the rapid fall lately and whether you think there could be a recovery.
Regards Jerry Gazarek

Q: Your thoughts on this company? Is it a buy, sell or hold?

Q: Hi Peter and Staff
No rush ... Happy New Year......just watched a BNN Market Call and guest tried to justify decline in his past pick JNJ by saying the numbers do not include the spinout (Kemba)? ........I held JNJ through that spin out period and never received any of the spinout. It would seem logical the price would drop after a spin out but how does that affect those who never got the spinout?

Thanks for all you do
Dennis